ReviewJAC-antimicrobial resistance2026
Oral nystatin for the prevention of antibiotic-related fungal peritonitis in peritoneal dialysis patients: a systematic review and meta-analysis of randomized and observational studies.
Review in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Fungal peritonitis is a severe complication in peritoneal dialysis (PD) patients, frequently occurring after antibiotic exposure. This systematic review and meta-analysis assessed whether oral nystatin administered concomitantly with antibiotics reduces the incidence of antibiotic-related fungal peritonitis (ARFP) compared with no prophylaxis. Methods: Following PRISMA guidelines, MEDLINE, PubMed and Embase were searched up to 1 October 2025 for randomized and observational studies enrolling adult PD patients who received systemic antibiotics with or without oral nystatin prophylaxis. The primary outcome was the odds of ARFP. ORs were pooled using random-effects models. This systematic review and meta-analysis was registered in PROSPERO (CRD420251154535). Results: Four prospective observational studies and one randomized controlled trial (RCT), comprising 2060 PD patients, were included. ARFP yielded 13 events among 1044 peritonitis episodes in the nystatin-treated patients versus 31 among 1016 in the control group (OR 0.53; 95% CI, 0.18-1.57). In the two studies (one observational and one RCT) reporting prescription-level data, nystatin was significantly associated with ARFP reduction (7 events out of 2205 prescriptions in the prophylaxis group versus 16/1724; OR 0.35; 95% CI, 0.15-0.87). Conclusions: Oral nystatin administered during antibiotic therapy was associated with a numerically lower rate of ARFP in PD patients, although all pooled estimates were based on unadjusted data and a limited number of events, thus precluding any certain causal inference. However, given its favourable safety profile and local action, nystatin may represent a valid candidate for a prophylactic strategy warranting further evaluation in contemporary, adequately powered randomized trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.